SCHEMBL30775340

SCHEMBL30775340

CCCNc1nccc(OC2CCNC2)n1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SYK P43405 4/20 0.46
CHRM1 P11229 1/20 0.42
CHRNB2 P17787 1/20 0.41
CHRNA4 P43681 1/20 0.41
CDC7 O00311 1/20 0.41
PRKCZ Q05513 1/20 0.38
HRH4 Q9H3N8 3/20 0.38
MERTK Q12866 2/20 0.37
CACNA2D1 P54289 1/20 0.37
ROCK1 Q13464 2/20 0.37
ROCK2 O75116 1/20 0.37
KCNH2 Q12809 1/20 0.37
AXL P30530 1/20 0.36
FLT3 P36888 1/20 0.36
TYRO3 Q06418 1/20 0.36
GAS6 Q14393 1/20 0.36
HRH3 Q9Y5N1 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30775276 0.90 SYK (0.47) SYKCHRM1CHRNB2CHRNA4PRKCZ
SCHEMBL30775239 0.88 SYK (0.46) SYKCHRM1CHRNB2CHRNA4PRKCZ
SCHEMBL30775406 0.84 HRH4 (0.52) SYKCHRNB2CHRNA4CDC7PRKCZ
SCHEMBL30775173 0.83 SYK (0.50) SYKCHRM1CHRNB2CHRNA4PRKCZ
SCHEMBL30775437 0.82 HRH4 (0.47) SYKCHRNB2CHRNA4PRKCZHRH4
SCHEMBL30775418 0.82 SYK (0.45) SYKCHRNB2CHRNA4PRKCZHRH4
SCHEMBL30775338 0.81 SYK (0.48) SYKCHRM1CHRNB2CHRNA4PRKCZ
SCHEMBL30775266 0.80 SYK (0.47) SYKCHRNB2CHRNA4PRKCZHRH4
SCHEMBL30757155 0.80 SYK (0.52) SYKCHRNB2CHRNA4PRKCZROCK1
SCHEMBL26987228 0.80 SYK (0.52) SYKCHRNB2CHRNA4PRKCZROCK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240025884-A1 COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF DONG-A ST CO., LTD. (KR) 2024-01-25 US claimed
US-12240836-B2 Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof DONG-A ST CO., LTD. (KR) 2025-03-04 US disclosed
US-20240025884-A1 COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF DONG-A ST CO., LTD. (KR) 2024-01-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12240836-B2 Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof EIF2AK4, GCN1, GCGR SYK 4838/4885CHRM1 4823/4885CHRNB2 3816/4885
US-20240025884-A1 COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF EIF2AK4, GCN1, GCGR SYK 4838/4885CHRM1 4823/4885CHRNB2 3816/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.